Singapore at a glance
- Population
- 6.1 million 2025
- Life expectancy at birth
- 83.3 years, 2024
- People aged 65 and over
- 14.2 % of people, 2025
- Health spending per person
- 3,922 US$ per person, 2023
- Doctors
- 2.83 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Singapore Plasma-Derived Therapies Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$42.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $39.6 Mn | — | — |
| 2025 (base) | $42.8 Mn | +$3.2 Mn | — |
| 2026 (forecast) | $46.2 Mn | +$3.4 Mn | +8% |
| 2027 (forecast) | $49.9 Mn | +$3.7 Mn | +16.6% |
| 2028 (forecast) | $53.9 Mn | +$4.0 Mn | +26% |
| 2029 (forecast) | $58.2 Mn | +$4.3 Mn | +36% |
| 2030 (forecast) | $62.9 Mn | +$4.7 Mn | +46.9% |
| 2031 (forecast) | $67.9 Mn | +$5.0 Mn | +58.7% |
| 2032 (forecast) | $73.4 Mn | +$5.4 Mn | +71.4% |
| 2033 (forecast) | $79.2 Mn | +$5.9 Mn | +85.1% |
| 2034 (forecast) | $85.6 Mn | +$6.3 Mn | +99.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $42.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $85.6 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, application and end user (see all) |
| Key players | CSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma, Kedrion Biopharma (see all) |
| Regulator in Singapore | HSASource: Health Sciences Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Plasma-derived therapies are medicines made from donated blood plasma, such as immunoglobulins, albumin and clotting factors.
Key segments of the plasma-Derived Therapies market include product (Immunoglobulins, Albumin and Coagulation Factors) and application (Immunology, Hematology and Critical Care).
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.
Ready-to-use formulations, biosimilars and supply security programmes give the plasma-Derived Therapies market room to grow.
Drug shortages, price controls, generic competition and strict hospital budgets hold back the plasma-Derived Therapies market.
The plasma-Derived Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Therapeutic products need registration with the Health Sciences Authority (HSA).[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2]
[1] Health Sciences Authority. Checked 14 Nov 2026.
[2] CPF Board, MediShield Life. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for plasma-Derived Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.
What doctors and scientists are doing in Plasma-Derived Therapies right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
Singapore · 3 shared keywords
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Singapore · 1 shared keyword
Medical Devices · Singapore
Healthcare Services · Singapore
Healthcare Services · Singapore
Healthcare Services · Singapore
Healthcare Services · Singapore
Healthcare Services · Singapore